Clinical Trial Update: ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 trial ACHIEVE evaluating adoptive cellular therapy with ex-vivo expanded allogeneic γδ T-lymphocytes (TCB008) for refractory or relapsed acute myeloid l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• TCB008 (TCB008)

Snippet

Sponsor: TC Biopharm | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED